Inhibikase Therapeutics, Inc.
As of Oct 22, 2026, Inhibikase Therapeutics is in Stage 3, the topping phase, now in week 2 (since Oct 12, 2026). It closed at $1.63, 35.3% below its 52-week high and below its 200-day average, which is rising.
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arteria… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is IKT early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
IKT among Biotechnology178th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …178 | IKT | Stage 3 · wk 2 | 57 | −24.2% |
Inhibikase Therapeutics: quick answers
What stage is Inhibikase Therapeutics in?
As of Oct 22, 2026, Inhibikase Therapeutics (IKT) is in Stage 3, the topping phase. It entered Stage 3 on Oct 12, 2026 and is in week 2. What the four stages mean
Is Inhibikase Therapeutics in an uptrend?
Its uptrend has stalled. Inhibikase Therapeutics is in Stage 3, the topping phase that follows an advance. It trades 16.0% below its 200-day average, which is rising.
How far is Inhibikase Therapeutics from its 52-week high?
Inhibikase Therapeutics closed at $1.63 on Oct 22, 2026, 35.3% below its 52-week high of $2.52. Its 52-week low is $1.41.
How has Inhibikase Therapeutics performed over the past year?
As of Oct 22, 2026, Inhibikase Therapeutics is up 3.2% over the past year and down 16.4% so far in 2026.
Which sector and industry is Inhibikase Therapeutics in?
Inhibikase Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.